NVISION IMAGING TECHNOLOGIES GMBH

Their core work

NVision is a German deep-tech SME that develops diamond-based quantum sensing technology for medical imaging applications. They specialize in hyperpolarization techniques using nitrogen-vacancy (NV) centers in diamond to dramatically enhance MRI signal strength, enabling metabolic imaging for precision diagnostics. Their core work bridges quantum physics and clinical imaging — turning laboratory quantum sensing breakthroughs into commercially viable molecular imaging tools, with a particular focus on cardiovascular disease diagnostics.

What they specialise in

How they've shifted over time

NVision's trajectory shows a clear shift from fundamental quantum technology exploration toward concrete medical applications. Their early projects (HYPERDIAMOND 2016, QUSMI 2017) focused on proving that diamond quantum technologies could work for imaging — essentially demonstrating feasibility. By 2018, their later projects (MetaboliQs, ASTERIQS) reveal a company that has moved into application-specific development: metabolic imaging for cardiovascular diagnostics, and advanced NV-center sensing with AFM and NMR capabilities. The evolution is from "can we do this?" to "here's the clinical product path."

NVision is moving from quantum physics research toward medical device commercialization, making them increasingly relevant for clinical imaging and diagnostics partnerships.

How they like to work

NVision operates primarily as a specialist partner (4 of 5 projects as participant), contributing deep diamond quantum sensing expertise to larger consortia. They coordinated one small CSA project (QUSMI, EUR 78K) — likely a feasibility or coordination study — while their participant roles in RIA projects carry substantially larger budgets. With 50 unique partners across 12 countries, they connect widely rather than repeatedly, suggesting they are sought after as a niche technology provider that different research groups want access to.

NVision has built a broad European network of 50 partners across 12 countries through just 5 projects, indicating participation in large, multi-partner consortia typical of quantum technology and medical imaging research. Their network spans both quantum physics research groups and medical imaging institutions.

What sets them apart

NVision occupies an exceptionally rare niche: they are one of very few companies worldwide that can translate diamond nitrogen-vacancy quantum physics into practical medical imaging technology. While many university labs work on NV-center science, NVision as a private SME is positioned to commercialize these advances — sitting exactly at the gap between quantum physics research and clinical MRI products. For consortium builders, they bring both the quantum hardware expertise and the commercial translation perspective that academic partners typically lack.

Highlights from their portfolio

• MetaboliQs
  Largest project (EUR 1.4M to NVision) — applies room-temperature diamond quantum dynamics to cardiovascular metabolic imaging, representing their clearest path to a clinical product.
• ASTERIQS
  Major quantum sensing consortium (EUR 590K) advancing diamond NV-center technology across multiple measurement modalities including AFM, NMR, and magnetic field sensing.
• HYPERDIAMOND
  Their earliest H2020 project bridging quantum tech and health — developed diamond nanoparticle targeted probes for hyperpolarized MRI, establishing NVision's dual quantum-medical identity.